RT Journal Article
T1 Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.
A1 Cattrini, Carlo
A1 Castro, Elena
A1 Lozano, Rebeca
A1 Zanardi, Elisa
A1 Rubagotti, Alessandra
A1 Boccardo, Francesco
A1 Olmos, David
K1 Abiraterone acetate
K1 Apalutamide
K1 Docetaxel
K1 Enzalutamide
K1 Hormone-naïve prostate cancer
K1 Hormone-sensitive prostate cancer
K1 Radiotherapy
AB The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact that several high-quality, randomized, controlled phase 3 trials have been conducted in this setting, no direct comparison is currently available among the different strategies. Inadequate power, absence of preplanning and small sample size frequently affect the subgroup analyses according to disease volume or patient's risk. The choice between ADT alone and ADT combined with docetaxel, abiraterone acetate, enzalutamide, apalutamide or radiotherapy to the primary tumor remains challenging. Factors that are related to the tumor, patient or drug side effects, currently guide these clinical decisions. This comprehensive review aims to indirectly compare the phase 3 trials in the mHSPC setting, in order to extrapolate data useful for treatment selection, providing also perspectives on future biomarkers.
PB MDPI
SN 2072-6694
YR 2019
FD 2019-09-12
LK http://hdl.handle.net/10668/14537
UL http://hdl.handle.net/10668/14537
LA en
NO Cattrini C, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, et al. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel). 2019 Sep 12;11(9):1355
DS RISalud
RD Apr 18, 2025